Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Olivier, CB; Weik, P; Meyer, M; Weber, S; Anto-Michel, N; Diehl, P; Zhou, Q; Geisen, U; Bode, C; Moser, M.
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Thromb Res. 2016; 138(2):63-68
Doi: 10.1016/j.thromres.2015.10.038
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Anto Michel Nathaly
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Novel (or non-vitamin K antagonist) oral anti-coagulants (NOACs) are antagonists of coagulation factors (F) Xa (rivaroxaban) or IIa (dabigatran), and their non-inferiority compared with vitamin K antagonists has been demonstrated in patients with non-valvular atrial fibrillation. However, it is still not fully understood if and how dabigatran and rivaroxaban impact platelet function. This observational study aimed to assess platelet function in patients receiving dabigatran or rivaroxaban. This was a single centre, observational study quantifying platelet aggregation in 90 patients treated with NOACs by multiple electrode aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly higher in 35 patients receiving dabigatran (d) compared with control (c) patients (d 108±31 vs. c 85±30arbitrary units [AU]∗min, p<0.001). Patients receiving rivaroxaban (r) showed no differences compared with the control group (r 88±32 vs. c 85±30AU∗min, p=0.335). In intraindividual time courses of 16 patients, a significantly higher aggregation was found after the administration of dabigatran (before vs. after; 83±29 vs. 100±31AU∗min, p=0.009). In this observational study, the TRAP-induced platelet aggregation was enhanced in cardiovascular patients receiving dabigatran. This might be explained by a change in the expression profile of thrombin receptors on the surface of platelets. Rivaroxaban had no influence on platelet aggregation. Copyright © 2015 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Antithrombins - pharmacology
- Antithrombins - therapeutic use
- Atrial Fibrillation - drug therapy
- Blood Platelets - drug effects
- Dabigatran - pharmacology
- Dabigatran - therapeutic use
- Female -
- Humans -
- Male -
- Middle Aged -
- Platelet Aggregation - drug effects
- Pulmonary Embolism - drug therapy
- Receptors, Thrombin - metabolism
- Rivaroxaban - pharmacology
- Rivaroxaban - therapeutic use
- Venous Thrombosis - drug therapy
- Find related publications in this database (Keywords)
- Dabigatran
- Rivaroxaban
- Platelet
- Aggregation